Trabecular bone score and quantitative ultrasound measurements in the assessment of bone health in breast cancer survivors assuming aromatase inhibitors Aromatase inhibitor, Cancer, Hologic, Italy, Quantitative ultrasound, Secondary osteoporosis
Cancer Treatment and Bone Health Aromatase inhibitor, Breast cancer, Cancer, Review, Secondary osteoporosis, Tamoxifen, UK
Estudio de la base genética de la reducción del Trabecular Bone Score relacionada con los inhibidores de la aromatasa Aromatase inhibitor, Breast cancer, Cancer, Genetic factors, Sensitivity and Specificity, Spain
Osteoporosis and musculoskeletal complications related to therapy of breast cancer Aromatase inhibitor, Breast cancer, Cancer, Review, Secondary osteoporosis, USA
Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer Aromatase inhibitor, Breast cancer, Cancer, GE-Lunar, Longitudinal, Secondary osteoporosis, South Korea
Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone score Aromatase inhibitor, Breast cancer, Cancer, GE-Lunar, Secondary osteoporosis, TBS Osteo - All publications about FRAX, USA
TBS and BMD at the end of AI-therapy: A prospective study of the B-ABLE cohort Aromatase inhibitor, Bisphosphonate, Breast cancer, Cancer, Hologic, Longitudinal, Secondary osteoporosis, Spain, Tamoxifen, Treatment (anti-osteoporotic treatments)
Risedronate may preserve bone microarchitecture in breast cancer survivors on aromatase inhibitors: A randomized, controlled clinical trial Aromatase inhibitor, Bisphosphonate, Breast cancer, Cancer, Hologic, Longitudinal, Risedronate, Secondary osteoporosis, Treatment (anti-osteoporotic treatments), USA
Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss: results of the ProBONE II substudy. Aromatase inhibitor, Bisphosphonate, Breast cancer, GE-Lunar, Germany, Longitudinal, Secondary osteoporosis, Treatment (anti-osteoporotic treatments), Zoledronate
Effects of Exemestane and Tamoxifen treatment on bone texture analysis assessed by TBS in comparison with bone mineral density assessed by DXA in women with breast cancer Aromatase inhibitor, Breast cancer, Cancer, Exemestane, GE-Lunar, Germany, Longitudinal, Secondary osteoporosis, Tamoxifen, Treatment (anti-osteoporotic treatments)